🔴 Lipocine is trading 7.69% down

Lipocine is trading at $1.44, down 7.69%, with no confirmed company-specific announcement explaining the October 19 decline.

• Supplied price context shows a second consecutive declining session after October 16.
• The latest listed company release was the October 7 Health Canada approval of TLANDO.
• Biotech was higher in the supplied sector context, but available evidence does not establish a specific catalyst for Lipocine’s move lower.